Pharmacologic management of type 2 diabetes

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023 · see citing works

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

(1998) · The Lancet · doi:10.1016/s0140-6736(98)07037-8 · Cited by 8,247 · see citing works

Effects of Intensive Glucose Lowering in Type 2 Diabetes

(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888 · see citing works

10-year follow-up of intensive glucose control in type 2 diabetes

Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · see citing works

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397 · see citing works

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · see citing works

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

(1998) · PubMed · Cited by 4,290 · see citing works

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129 · see citing works

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079 · see citing works

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962 · see citing works

Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: Executive Summary

(1998) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/68.4.899 · Cited by 2,705 · see citing works

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08905-5 · Cited by 2,543 · see citing works

Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes Mellitus<SUBTITLE>Progressive Requirement for Multiple Therapies (UKPDS 49)</SUBTITLE>

Turner, R. C. (1999) · JAMA · doi:10.1001/jama.281.21.2005 · Cited by 2,375 · see citing works

The Wisconsin Epidemiologic Study of Diabetic Retinopathy

Klein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030398010 · Cited by 1,890 · see citing works

Basal insulin and cardiovascular and other outcomes in dysglycemia

The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636 · see citing works

Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance: The STOP-NIDDM Trial

Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., & for The STOP-NIDDM Trial Research Group (2003) · JAMA · doi:10.1001/jama.290.4.486 · Cited by 1,624 · see citing works

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · see citing works

The Wisconsin Epidemiologic Study of Diabetic Retinopathy

Klein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030405011 · Cited by 1,482 · see citing works

Contributions of Fasting and Postprandial Plasma Glucose Increments to the Overall Diurnal Hyperglycemia of Type 2 Diabetic Patients

Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461 · see citing works

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60953-3 · Cited by 1,393 · see citing works

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

Ray, K. K., Seshasai, S. R. K., Wijesuriya, S., Sivakumaran, R., Nethercott, S., Preiss, D., Erqou, S., & Sattar, N. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60697-8 · Cited by 1,383 · see citing works

Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 Diabetes

Aschner, P. J., Kipnes, M. S., Lunceford, J. K., Sanchez, M., Mickel, C., Williams‐Herman, D., & for the Sitagliptin Study 021 Group (2006) · Diabetes Care · doi:10.2337/dc06-0703 · Cited by 878 · see citing works

Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials

Boussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., Lafont, S., Bergeonneau, C., Kassai, B., Erpeldinger, S., Wright, J. M., Gueyffier, F., & Cornu, C. (2011) · BMJ · doi:10.1136/bmj.d4169 · Cited by 803 · see citing works

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone

Charbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group (2006) · Diabetes Care · doi:10.2337/dc06-0706 · Cited by 790 · see citing works

Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial

Weng, J., Li, Y., Xu, W., Shi, L., Zhang, Q., Zhu, D., Hu, Y., Zhou, Z., Yan, X., Tian, H., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60762-x · Cited by 780 · see citing works

Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis

Home, P. D., Pocock, S. J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. V. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073394 · Cited by 761 · see citing works

β-Cell Failure in Diabetes and Preservation by Clinical Treatment

WAJCHENBERG, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 716 · see citing works

Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: Randomised placebo controlled trial

de Jager, J., Kooy, A., Lehert, P., Wulffele, M. G., van der Kolk, J., Bets, D., Verburg, J., Donker, A. J. M., & Stehouwer, C. D. A. (2010) · BMJ · doi:10.1136/bmj.c2181 · Cited by 702 · see citing works

Three-year efficacy of complex insulin regimens in type 2 diabetes

Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., & Paul, S. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905479 · Cited by 667 · see citing works

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

Hollander, P. A., Elbein, S. C., Hirsch, I. B., Kelley, D., McGill, J., Taylor, T., Weiss, S. R., Crockett, S. E., Kaplan, R. A., Comstock, J., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1288 · Cited by 654 · see citing works

Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995–2005: a population-based study

Lipscombe, L. L., & Hux, J. E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60361-4 · Cited by 628 · see citing works

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

Aronoff, S., Rosenblatt, S., Braithwaite, S. S., Egan, J. W., Mathisen, A. L., & Schneider, R. (2000) · Diabetes Care · doi:10.2337/diacare.23.11.1605 · Cited by 626 · see citing works

Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone

Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L. (2011) · Diabetes Care · doi:10.2337/dc10-1068 · Cited by 625 · see citing works

Rosiglitazone Revisited

Nissen, S. E., & Wolski, K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.207 · Cited by 590 · see citing works

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

Yki‐Järvinen, H., Dressler, A., Ziemen, M., & HOE 901/300s Study Group (2000) · Diabetes Care · doi:10.2337/diacare.23.8.1130 · Cited by 578 · see citing works

Sulfonylurea Inadequacy

Wright, A. D., Burden, A. C., Paisey, R., Cull, C. A., Holman, R. R., & for the U.K. Prospective Diabetes Study Group (2002) · Diabetes Care · doi:10.2337/diacare.25.2.330 · Cited by 553 · see citing works

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

Loke, Y. K., Singh, S., & Furberg, C. D. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080486 · Cited by 553 · see citing works

Effect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes Mellitus

Fonseca, V. A., Rosenstock, J., Patwardhan, R., & Salzman, A. (2000) · JAMA · doi:10.1001/jama.283.13.1695 · Cited by 538 · see citing works

Rosiglitazone-Associated Fractures in Type 2 Diabetes

Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., Holman, R. R., Kravitz, B. G., Yu, D., Heise, M. A., Aftring, R. P., et al. (2008) · Diabetes Care · doi:10.2337/dc07-2270 · Cited by 537 · see citing works

Efficacy of Metformin in Type II Diabetes

Garber, A. J., Duncan, T. G., Goodman, A. M., Mills, D. J., & Rohlf, J. L. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00254-4 · Cited by 519 · see citing works

Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes

Lebovitz, H. E., Dole, J., Patwardhan, R., Rappaport, E. B., & Freed, M. I. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7157 · Cited by 518 · see citing works

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes: A Randomized, Controlled Trial

Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506 · see citing works

Oral antihyperglycemic therapy for type 2 diabetes mellitus

CHENG, A. Y. Y. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.1031414 · Cited by 499 · see citing works

Twelve- and 52-Week Efficacy of the Dipeptidyl Peptidase IV Inhibitor LAF237 in Metformin-Treated Patients With Type 2 Diabetes

Ahrén, B., Gomis, R., Standl, E., Mills, D., & Schweizer, A. (2004) · Diabetes Care · doi:10.2337/diacare.27.12.2874 · Cited by 487 · see citing works

Basal Insulin Therapy in Type 2 Diabetes

Rosenstock, J., Schwartz, S. L., Clark, C. M., Park, G. D., Donley, D. W., & Edwards, M. B. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.631 · Cited by 477 · see citing works

Hypoglycaemia in Type 2 diabetes

Amiel, S. A., Dixon, T., Mann, R., & Jameson, K. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02341.x · Cited by 472 · see citing works

A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

Holman, R. R., Cull, C. A., & Turner, R. C. (1999) · Diabetes Care · doi:10.2337/diacare.22.6.960 · Cited by 451 · see citing works

Implications of the United Kingdom Prospective Diabetes Study

American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s28 · Cited by 446 · see citing works

Comparison of Bedtime Insulin Regimens in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial

Yki-Järvinen, H., Ryysy, L., Nikkilä, K., Tulokas, T., Vanamo, R., & Heikkilä, M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-5-199903020-00002 · Cited by 433 · see citing works

The Efficacy of Acarbose in the Treatment of Patients with Non–Insulin-Dependent Diabetes Mellitus: A Multicenter, Controlled Clinical Trial

Chiasson, J., Josse, R. G., Hunt, J. A., Palmason, C., Rodger, N. W., Ross, S. A., Ryan, E. A., Tan, M. H., & Wolever*, T. M. S. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-12-199412150-00004 · Cited by 433 · see citing works

Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes

Janka, H. U., Plewe, G., Riddle, M. C., Kliebe-Frisch, C., Schweitzer, M. A., & Yki-Järvinen, H. (2005) · Diabetes Care · doi:10.2337/diacare.28.2.254 · Cited by 414 · see citing works

United Kingdom Prospective Diabetes Study 24: A 6-Year, Randomized, Controlled Trial Comparing Sulfonylurea, Insulin, and Metformin Therapy in Patients with Newly Diagnosed Type 2 Diabetes That Could Not Be Controlled with Diet Therapy

(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-3-199802010-00001 · Cited by 385 · see citing works

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study

EINHORN, D. F., Rendell, M., Rosenzweig, J. L., Egan, J. W., Mathisen, A. L., & Schneider, R. L. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)83039-8 · Cited by 367 · see citing works

Systematic review: glucose control and cardiovascular disease in type 2 diabetes

Kelly, T. N., Bazzano, L. A., Fonseca, V. A., Thethi, T. K., Reynolds, K., & He, J. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-6-200909150-00137 · Cited by 358 · see citing works

Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM): Results of the feasibility trial

Abraira, C., Colwell, J. A., Nuttall, F. Q., Sawin, C. T., Nagel, N. J., Comstock, J. P., Emanuele, N. V., Levin, S. R., Henderson, W., Lee, H. S., et al. (1995) · Diabetes Care · doi:10.2337/diacare.18.8.1113 · Cited by 355 · see citing works

Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: The HEART2D trial

Raz, I., Wilson, P. W. F., Strojek, K., Kowalska, I., Bozikov, V., Gitt, A. K., Jermendy, G., Campaigne, B. N., Kerr, L., Milicevic, Z., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1671 · Cited by 351 · see citing works

A Randomized Trial of Rosiglitazone Therapy in Patients With Inadequately Controlled Insulin-Treated Type 2 Diabetes

Raskin, P., Rendell, M., Riddle, M. C., Dole, J., Freed, M. I., & Rosenstock, J. (2001) · Diabetes Care · doi:10.2337/diacare.24.7.1226 · Cited by 345 · see citing works

Alpha-glucosidase inhibitors for type 2 diabetes mellitus

Van de Laar, F. A., Lucassen, P. L., Akkermans, R. P., Van de Lisdonk, E. H., Rutten, G. E., & Van Weel, C. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003639.pub2 · Cited by 335 · see citing works

Glimepiride Combined with Morning Insulin Glargine, Bedtime Neutral Protamine Hagedorn Insulin, or Bedtime Insulin Glargine in Patients with Type 2 Diabetes

Fritsche, A., Schweitzer, M. A., H�ring, H.-U., & and the 4001 Study Group* (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-12-200306170-00006 · Cited by 331 · see citing works

Effect of Troglitazone in Insulin-Treated Patients with Type II Diabetes Mellitus

Schwartz, S. L., Raskin, P., Fonseca, V. A., & Graveline, J. F. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381302 · Cited by 327 · see citing works

Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus

Yki-Järvinen, H., Kauppila, M., Kujansuu, E., Lahti, J., Marjanen, T., Niskanen, L., Rajala, S., Ryysy, L., Salo, S., Seppälä, P., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211123272005 · Cited by 324 · see citing works

The Effect of Oral Antidiabetic Agents on A1C Levels

Sherifali, D., Nerenberg, K. A., Pullenayegum, E., Cheng, J., & Gerstein, H. C. (2010) · Diabetes Care · doi:10.2337/dc09-1727 · Cited by 317 · see citing works

Clinical Efficacy of Orlistat Therapy in Overweight and Obese Patients With Insulin-Treated Type 2 Diabetes

Kelley, D. E., Bray, G. A., Pi-Sunyer, F. X., Klein, S., Hill, J., Miles, J., & Hollander, P. (2002) · Diabetes Care · doi:10.2337/diacare.25.6.1033 · Cited by 314 · see citing works

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

Vilsbøll, T., Rosenstock, J., Yki‐Järvinen, H., Cefalu, W. T., Chen, Y., Luo, E., Musser, B., Andryuk, P. J., Ling, Y., Kaufman, K. D., et al. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01173.x · Cited by 305 · see citing works

Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial

Bretzel, R. G., Nuber, U., Landgraf, W., Owens, D. R., Bradley, C., & Linn, T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60485-7 · Cited by 303 · see citing works

Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin

Miles, J. M., Leiter, L., Hollander, P., Wadden, T., Anderson, J. W., Doyle, M., Foreyt, J., Aronne, L., & Klein, S. (2002) · Diabetes Care · doi:10.2337/diacare.25.7.1123 · Cited by 286 · see citing works

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

Kipnes, M. S., Krosnick, A., Rendell, M., Egan, J. W., Mathisen, A. L., & Schneider, R. L. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00713-6 · Cited by 281 · see citing works

Lower within‐subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes

Haak, T., Tiengo, A., Draeger, E., Suntum, M., & Waldhäusl, W. K. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00373.x · Cited by 277 · see citing works

GUIDE study: double‐blind comparison of once‐daily gliclazide MR and glimepiride in type 2 diabetic patients

Schernthaner, G., Grimaldi, A., Di Mario, U., Drzewoski, J., Kempler, P., Kvapil, M., Novials, A., Rottiers, R., Rutten, G. E. H. M., & Shaw, K. M. (2004) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2004.01381.x · Cited by 271 · see citing works

Reappraisal of Metformin Efficacy in the Treatment of Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials

Boussageon, R., Supper, I., Bejan-Angoulvant, T., Kellou, N., Cucherat, M., Boissel, J.-P., Kassai, B., Moreau, A., Gueyffier, F., & Cornu, C. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001204 · Cited by 266 · see citing works

Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide

Holstein, A., Plaschke, A., & Egberts, E. (2001) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.235 · Cited by 264 · see citing works

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

Moses, R. G., Slobodniuk, R., BOYAGES, S. C., Colagiuri, S., Kidson, W., Carter, J., Donnelly, T., Moffitt, P. S., & Hopkins, H. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.119 · Cited by 246 · see citing works

Short-Term Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetes

Ryan, E. A., Imes, S., & Wallace, C. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1028 · Cited by 241 · see citing works

Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis

Singh, S. R., Ahmad, F., Lal, A., Yu, C., Bai, Z., & Bennett, H. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.081041 · Cited by 241 · see citing works

Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

Horton, E. S., Clinkingbeard, C., Gatlin, M. R., Foley, J. E., Mallows, S., & Shen, S. (2000) · Diabetes Care · doi:10.2337/diacare.23.11.1660 · Cited by 239 · see citing works

Effects of Metformin in Patients with Poorly Controlled, Insulin-Treated Type 2 Diabetes Mellitus

Avilés-Santa, L. M., Sinding, J., & Raskin, P. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-3-199908030-00004 · Cited by 222 · see citing works

Lower Baseline Glycemia Reduces Apparent Oral Agent Glucose-Lowering Efficacy

Bloomgarden, Z. T., Dodis, R., Viscoli, C. M., Holmboe, E. S., & Inzucchi, S. E. (2006) · Diabetes Care · doi:10.2337/dc06-1120 · Cited by 219 · see citing works

Sibutramine

McNeely, W., & Goa, K. L. (1998) · Drugs · doi:10.2165/00003495-199856060-00019 · Cited by 219 · see citing works

A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes

Frederich, R. C., Alexander, J. H., Fiedorek, F. T., Donovan, M., Berglind, N., Harris, S., Chen, R. K., Wolf, R., & Mahaffey, K. W. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.05.2138 · Cited by 217 · see citing works

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes

Raskin, P., Rappaport, E. B., Cole, S. T., Yan, Y., Patwardhan, R., & Freed, M. I. (2000) · Diabetologia · doi:10.1007/s001250050045 · Cited by 214 · see citing works

Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes

Gaziano, J. M., Cincotta, A. H., O’Connor, C. M., Ezrokhi, M., Rutty, D., Ma, Z., & Scranton, R. E. (2010) · Diabetes Care · doi:10.2337/dc09-2009 · Cited by 214 · see citing works

Long-acting insulin analogues versus NPH human insulin in type 2 diabetes

Monami, M., Marchionni, N., & Mannucci, E. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.04.007 · Cited by 211 · see citing works

A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose‐lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study

Gerstein, H. C., Yale, J. ‐., Harris, S. B., Issa, M., Stewart, J. A., & Dempsey, E. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01881.x · Cited by 197 · see citing works

Symptomatic Hypoglycemia in NIDDM Patients Treated With Oral Hypoglycemic Agents

Jennings, A. M., Wilson, R. M., & Ward, J. D. (1989) · Diabetes Care · doi:10.2337/diacare.12.3.203 · Cited by 194 · see citing works

Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group

Anderson, J. H. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.157.11.1249 · Cited by 193 · see citing works

Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: A network meta-analysis

Liu, S. ‐., Tu, Y. ‐., Chien, M. ‐., & Chien, K. ‐. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01606.x · Cited by 180 · see citing works

Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients

Boehm, B. O., Home, P., Behrend, C., Kamp, N., & Olinder, A. L. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00733.x · Cited by 176 · see citing works

Combination of Insulin and Metformin in the Treatment of Type 2 Diabetes

Wulffelé, M. G., Kooy, A., Lehert, P., Bets, D., Ogterop, J. C., van der Burg, B. B., Donker, A. J. M., & Stehouwer, C. D. A. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2133 · Cited by 174 · see citing works

Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin

Arnolds, S., Dellweg, S., Clair, J., Dain, M., Nauck, M. A., Rave, K., & Kapitza, C. (2010) · Diabetes Care · doi:10.2337/dc09-2191 · Cited by 167 · see citing works

Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin

Barnett, A. H., Charbonnel, B., Donovan, M., & Fleming, D. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.665046 · Cited by 162 · see citing works

Insulin Glulisine Provides Improved Glycemic Control in Patients With Type 2 Diabetes

Dailey, G., Rosenstock, J., Moses, R. G., & Ways, K. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2363 · Cited by 153 · see citing works

Efficacy of 24-Week Monotnerapy With Acarbose, Glibenclamide, or Placebo in NIDDM Patients: The Essen Study

Hoffmann, J., & Spengler, M. (1994) · Diabetes Care · doi:10.2337/diacare.17.6.561 · Cited by 146 · see citing works

Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials

Monami, M., Marchionni, N., & Mannucci, E. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0101 · Cited by 146 · see citing works

Efficacy of Insulin and Sulfonylurea Combination Therapy in Type II Diabetes

Johnson, J. L. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440030049007 · Cited by 145 · see citing works

Combined randomised controlled trial experience of malignancies in studies using insulin glargine

Home, P., & Lagarenne, P. (2009) · Diabetologia · doi:10.1007/s00125-009-1530-5 · Cited by 141 · see citing works

Meglitinide analogues for type 2 diabetes mellitus

Black, C., Donnelly, P., McIntyre, L., Royle, P., Shepherd, J., & Thomas, S. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004654.pub2 · Cited by 140 · see citing works

Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes

Garber, A. J., Larsen, J. L., Schneider, S. H., Piper, B. A., Henry, D. A., & The Glyburide/Metformin Initial Therapy Study Group (2002) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2002.00211.x · Cited by 138 · see citing works

Clinical Evaluation of Glimepiride versus Glyburide in NIDDM in a Double-Blind Comparative Study

Dills, D. G., & Schneider, J. (1996) · Hormone and Metabolic Research · doi:10.1055/s-2007-979831 · Cited by 133 · see citing works

Mealtime Treatment With Insulin Analog Improves Postprandial Hyperglycemia and Hypoglycemia in Patients With Non-Insulin-Dependent Diabetes Mellitus

Anderson, J. H. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440320157015 · Cited by 133 · see citing works

A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.

Wolffenbuttel, B. H. R., & Landgraf, R. (1999) · Diabetes Care · doi:10.2337/diacare.22.3.463 · Cited by 129 · see citing works

A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.

Damsbo, P., Clauson, P., Marbury, T. C., & Windfeld, K. (1999) · Diabetes Care · doi:10.2337/diacare.22.5.789 · Cited by 118 · see citing works

Improved mealtime treatment of diabetes mellitus using an insulin analogue

Anderson, J. (1997) · Clinical Therapeutics · doi:10.1016/s0149-2918(97)80073-2 · Cited by 118 · see citing works

Glibenclamide vs Gliclazide in Type 2 Diabetes of the Elderly

Tessier, D., Dawson, K., Tétrault, J. P., Bravo, G., & Meneilly, G. S. (1994) · Diabetic Medicine · doi:10.1111/j.1464-5491.1994.tb00256.x · Cited by 116 · see citing works

Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus

Nolan, J. J., Jones, N. P., Patwardhan, R., & Deacon, L. F. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00269.x · Cited by 116 · see citing works

Improved postprandial glycaemic controls with insulin Aspart in type 2 diabetic patients treated with insulin

Rosenfalck, A. M., Thorsby, P. M., Kjems, L., Birkeland, K. I., Dejgaard, A., Hanssen, K. F., & Madsbad, S. (2000) · Acta Diabetologica · doi:10.1007/s005920070034 · Cited by 113 · see citing works

Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials

Monami, M., Cremasco, F., Lamanna, C., Colombi, C., Desideri, C. M., Iacomelli, I., Marchionni, N., & Mannucci, E. (2011) · Experimental Diabetes Research · doi:10.1155/2011/215764 · Cited by 112 · see citing works

A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin

Berne, C., & the Orlistat Swedish Type 2 diabetes Study Group (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01474.x · Cited by 112 · see citing works

A Meta-Analysis of Placebo-Controlled Clinical Trials Assessing the Efficacy and Safety of Incretin-Based Medications in Patients with Type 2 Diabetes

Fakhoury, W. K. H., LeReun, C., & Wright, D. (2010) · Pharmacology · doi:10.1159/000314690 · Cited by 110 · see citing works

Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group.

Roach, P. J., Yue, L., & Arora, V. K. (1999) · Diabetes Care · doi:10.2337/diacare.22.8.1258 · Cited by 109 · see citing works

No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis

Dejgaard, A., Lynggaard, H., Råstam, J., & Thomsen, M. (2009) · Diabetologia · doi:10.1007/s00125-009-1568-4 · Cited by 109 · see citing works

The Projection of Prevalence and Cost of Diabetes in Canada: 2000 to 2016

Ohinmaa, A. E., Jacobs, P., Simpson, S. H., & Johnson, J. A. (2016) · Cited by 107 · see citing works

The Effect of a Thiazolidinedione Drug, Troglitazone, on Glycemia in Patients with Type 2 Diabetes Mellitus Poorly Controlled with Sulfonylurea and Metformin: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Yale, J., Valiquett, T. R., Ghazzi, M. N., Owens-Grillo, J. K., Whitcomb, R. W., Foyt, H. L., & for the Troglitazone Triple-Therapy Study Group* (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-9_part_1-200105010-00010 · Cited by 102 · see citing works

Inhaled Insulin Provides Improved Glycemic Control in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Agents A Randomized Controlled Trial

Weiss, S. R. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.19.2277 · Cited by 98 · see citing works

Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis

Mannucci, E., Monami, M., & Marchionni, N. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00934.x · Cited by 96 · see citing works

Implications of the United Kingdom Prospective Diabetes Study

American Diabetes Association (1998) · Diabetes Care · doi:10.2337/diacare.21.12.2180 · Cited by 96 · see citing works

A Double-Blind Placebo-Controlled Trial Evaluating the Safety and Efficacy of Acarbose for the Treatment of Patients With Insulin-Requiring Type II Diabetes

Coniff, R. F., Shapiro, J. A., Seaton, T. B., et al. (1995) · Diabetes Care · doi:10.2337/diacare.18.7.928 · Cited by 92 · see citing works

Bedtime Insulin/Daytime Glipizide: Effective Therapy for Sulfonylurea Failures in NIDDM

shank, M. L., Prato, S. D., & DeFronzo, R. A. (1995) · Diabetes · doi:10.2337/diab.44.2.165 · Cited by 89 · see citing works

Initial treatment with rosiglitazone/metformin fixed‐dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes

Rosenstock, J., Rood, J. A., Cobitz, A. R., Biswas, N., Chou, H. S., & Garber, A. J. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00659.x · Cited by 87 · see citing works

Pharmacology of the Meglitinide Analogs

Malaisse, W. J. (2003) · Treatments in Endocrinology · doi:10.2165/00024677-200302060-00004 · Cited by 78 · see citing works

Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: A one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors

Derosa, G., Mugellini, A., Ciccarelli, L., Crescenzi, G., & Fogari, R. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80090-5 · Cited by 76 · see citing works

Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss

Jacob, S., Rabbia, M. A., Meier, M. K., & Hauptman, J. B. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00970.x · Cited by 72 · see citing works

A Placebo‐Controlled, Randomized Study of Glimepiride in Patients with Type 2 Diabetes Mellitus for Whom Diet Therapy is Unsuccessful

Schade, D. S., Jovanovic, L. G., & Schneider, J. (1998) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1998.tb04471.x · Cited by 71 · see citing works

Vitamin B12 status of patients treated with metformin: a cross-sectional cohort study

Hermann, L. S., Nilsson, B., & Wettre, S. (2004) · The British Journal of Diabetes · doi:10.1177/14746514040040060701 · Cited by 68 · see citing works

A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents.

Ross, S., Zinman, B., Campos, R. V., & Strack, T. R. (2001) · PubMed · Cited by 67 · see citing works

Combined metformin and insulin therapy for patients with type 2 diabetes mellitus

Ponssen, H., ELTE, J., Lehert, P., Schouten, J. P., & Bets, D. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)90005-5 · Cited by 61 · see citing works

Exenatide: From the Gila Monster to the Pharmacy

Triplitt, C. L., & Chiquette, E. (2006) · Journal of the American Pharmacists Association · doi:10.1331/154434506775268698 · Cited by 60 · see citing works

Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study

Rosenstock, J., Goldstein, B. J., Vinik, A., O’Neill, M., Porter, L. E., Heise, M. A., Kravitz, B. G., Dirani, R. G., Freed, M. I., & and the RESULT Study Group (2005) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00541.x · Cited by 60 · see citing works

Diabetes drug pioglitazone (Actos): risk of fracture

Meymeh, R. H., & Wooltorton, E. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.071177 · Cited by 52 · see citing works

Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Trials

Lincoff, A. M., Wolski, K., Nicholls, S. J., & Nissen, S. E. (2007) · JAMA · doi:10.1001/jama.298.10.1180 · Cited by 52 · see citing works

Erratum

(2002) · Diabetes Care · doi:10.2337/diacare.25.9.1671 · Cited by 52 · see citing works

Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone

Ristic, S., Collober‐Maugeais, C., Pecher, E., & Cressier, F. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01914.x · Cited by 47 · see citing works

Pharmacotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus: Rationale and Specific Agents

Cefalu, W. T., Waldman, S. A., & Ryder, S. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100156 · Cited by 46 · see citing works

Improvement in glycaemic control with rosiglitazone/metformin fixed‐dose combination therapy in patients with type 2 diabetes with very poor glycaemic control

Rosenstock, J., Rood, J. A., Cobitz, A. R., Huang, C., & Garber, A. J. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00648.x · Cited by 40 · see citing works

Gliclazide modified release: From once-daily administration to 24-hour blood glucose control

Harrower, A. (2000) · Metabolism · doi:10.1053/meta.2000.17823 · Cited by 30 · see citing works

Addition of Thiazolidinedione or Exenatide to Oral Agents in Type 2 Diabetes: A Meta-Analysis

Pinelli, N. R., Cha, R., Brown, M. B., & Jaber, L. A. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1l198 · Cited by 24 · see citing works

Thiazolidinediones: Do harms outweigh benefits?

Lipscombe, L. L. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.081713 · Cited by 21 · see citing works

Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis

Amori, R. E., Lau, J., & Pittas, A. G. (2007) · JAMA · doi:10.1001/jama.298.2.194 · Cited by 12 · see citing works

Control of Glucose Homeostasis by Incretin Hormones

Perfetti, R., Brown, T. A., Velikina, R., & Busselen, S. (1999) · Diabetes Technology & Therapeutics · doi:10.1089/152091599317215 · Cited by 10 · see citing works

The addition of pioglitazone in type 2 diabetics poorly controlled on insulin therapy: A meta-analysis

Tan, A., Cao, Y., Xia, N., Mo, Z., & Gao, F. (2010) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2010.03.018 · Cited by 7 · see citing works

Long-term Risk of Cardiovascular Events With Rosiglitazone: A Meta-analysis

Singh, S., Loke, Y. K., & Furberg, C. D. (2007) · JAMA · doi:10.1001/jama.298.10.1189 · Cited by 5 · see citing works

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications

Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376 · see citing works

Renoprotective effects of sodium-glucose cotransporter-2 inhibitors

Heerspink, H. J. L., Kosiborod, M., Inzucchi, S. E., & Cherney, D. Z. I. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.027 · Cited by 393 · see citing works

Can pulses play a role in improving cardiometabolic health? Evidence from systematic reviews and meta‐analyses

Viguiliouk, E., Blanco Mejia, S., Kendall, C. W. C., & Sievenpiper, J. L. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13312 · Cited by 101 · see citing works

Perirenal adipose tissue inflammation: novel insights linking metabolic dysfunction to renal diseases

Hammoud, S. H., AlZaim, I., Al-Dhaheri, Y., Eid, A. H., & El-Yazbi, A. F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.707126 · Cited by 87 · see citing works

Association Between Severe Hypoglycemia and Cardiovascular Disease Risk in Japanese Patients With Type 2 Diabetes

Goto, A., Goto, M., Terauchi, Y., Yamaguchi, N., & Noda, M. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002875 · Cited by 67 · see citing works

GDF-15 as a Weight Watcher for Diabetic and Non-Diabetic People Treated With Metformin

Ouyang, J., Isnard, S., Lin, J., Fombuena, B., Peng, X., Chen, Y., & Routy, J.-P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.581839 · Cited by 39 · see citing works

Criteria for Return to Contact Activities Following Cervical Spine Injury

Torg, J. S., & Glasgow, S. G. (1991) · Clinical Journal of Sport Medicine · doi:10.1097/00042752-199101000-00003 · Cited by 27 · see citing works

Preoperative Corticosteroids: A Contraindication to Lung Transplantation?

Wj, D. B., Mannes, G. P. M., & van der Bij, W. (1994) · CHEST Journal · doi:10.1378/chest.105.6.1908a · Cited by 38 · see citing works

Adverse drug reaction classification by health professionals: appropriate discrimination between allergy and intolerance?

Shakib, S., Caughey, G. E., Fok, J. S., et al. (2019) · Clinical and Translational Allergy · doi:10.1186/s13601-019-0259-6 · Cited by 26 · see citing works

244 Risk of contraindication and drug-drug interaction (DDI) with use of systemic immunosuppressants (IMMs) in adult patients with atopic dermatitis (AD)

Armstrong, A. W., Wei, W., García-Horton, V., et al. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.02.259 · Cited by 1 · see citing works

Contraindication to Lumbar Puncture

Levin, M. (2013) · Oxford University Press eBooks · doi:10.1093/med/9780199862856.003.0005